the agency's functions, the accuracy of the estimated burden, ways to enhance the quality, utility, and clarity of the information to be collected, and the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

DATES: Comments on the collection(s) of information must be received by the OMB desk officer by June 1, 2026.

ADDRESSES: Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to *www.reginfo.gov/public/do/PRAMain.* Find this particular information collection by selecting ''Currently under 30-day Review—Open for Public Comments'' or by using the search function.

To obtain copies of a supporting statement and any related forms for the proposed collection(s) summarized in this notice, please access the CMS PRA website by copying and pasting the following web address into your web browser: *https://www.cms.gov/Regulations-and-Guidance/Legislation/PaperworkReductionActof1995/PRA-Listing.*

FOR FURTHER INFORMATION CONTACT: William Parham at (410) 786–4669.

SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501–3520), federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. The term ''collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires federal agencies to publish a 30-day notice in the **Federal Register** concerning each proposed collection of information, including each proposed extension or reinstatement of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, CMS is publishing this notice that summarizes the following proposed collection(s) of information for public comment.

Information Collection

1. *Type of Information Collection Request:* New collection (Request for a new OMB control number); *Title of Information Collection:* Generic Clearance for the Collection of Medicare Current Beneficiary Survey (MCBS) Respondent ''Pulse'' Feedback; *Use:* This new request will allow the Centers for Medicare & Medicaid Services to efficiently utilize the MCBS to establish a new tool, the MCBS Pulse. This tool will establish a proactive, data-driven process that allows CMS to accomplish three goals: (1) Enhance operational efficiency by enabling decision-makers to obtain time-sensitive data points not available from other sources to inform program planning and development; (2) Add early design phase questionnaire testing capabilities by collecting rapid turnaround feedback on nascent questionnaire concepts; (3) Rapidly gather directional feedback from beneficiaries on emerging concerns for exploratory purposes and early-stage issue identification. Each MCBS Pulse survey will be brief and constrained in content, containing no more than five questions, that reflect an intentional prioritization of topics of greatest need to CMS stakeholders as well as a limitation of respondent burden and cost. Each individual MCBS Pulse survey will be incorporated into an existing MCBS round of data collection where it will be fielded for up to two weeks. The MCBS design includes three rounds per year, each lasting approximately 16 weeks. Given that each Pulse survey is exceptionally brief and fielded for only up to two weeks, CMS can conduct multiple Pulse surveys per round based on operational needs. *Form Number:* CMS–10948 (OMB control number: 0938–New); *Frequency:* Occasionally; *Affected Public:* Individuals or Households; *Number of Respondents:* 31,117; *Total Annual Responses:* 31,117; *Total Annual Hours:* 1,026. (For policy questions regarding this collection contact William Long at 410–786–7927.)

William N. Parham, III

Director, Division of Information Collections and Regulatory Impacts, Office of Strategic Operations and Regulatory Affairs.

[FR Doc. 2026–08542 Filed 4–30–26; 8:45 am]

BILLING CODE 4120–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

[CMS–1854–N]

Medicare Program: Rechartering, Membership, and Meeting Announcement for the Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests

AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.

ACTION: Notice.

SUMMARY: This notice announces the rechartering of the Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests (the Panel), appointment of five new members to the Panel, and the next public meeting dates for the Panel on Tuesday, July 14, 2026, and Wednesday, July 15, 2026. The purpose of the Panel is to advise the Secretary of the Department of Health and Human Services and the Administrator of the Centers for Medicare & Medicaid Services on issues related to clinical diagnostic laboratory tests.

DATES:

Meeting Dates: Tuesday, July 14, 2026, from 10:00 a.m. to 4:00 p.m. Eastern Daylight Time (E.D.T.) and Wednesday, July 15, 2026, from 10:00 a.m. to 4:00 p.m. E.D.T. The Panel is also expected to participate virtually in the Clinical Laboratory Fee Schedule (CLFS) Annual Public Meeting for Calendar Year (CY) 2027 on Wednesday, June 10, 2026. The Panel will also participate virtually in another public meeting on Tuesday, September 15, 2026, and Wednesday, September 16, 2026. Notice of the CLFS Annual Public Meeting for CY 2027 and the September meeting appear elsewhere in this issue of the **Federal Register**.

Deadline for Meeting Registration: May 29, 2026, 5:00 p.m. E.D.T.

Deadline for Requesting Special Accommodations: May 29, 2026, 5:00 p.m. E.D.T.

In-Person Attendance: If attending the meeting in person at the CMS Headquarters, registration is required and must be completed by May 29, 2026. For more information on how to register as an in-person attendee, see the ''Registration Instructions'' (section IV. of this notice).

Virtual Attendee Only: The public may also view this meeting via webinar or listen-only via teleconference. If attending the meeting via webinar, or listen-only via teleconference, registration is not required for non-speakers.

Webinar and Teleconference Meeting Information: Teleconference dial-in instructions, and related webinar details will be posted on the meeting agenda, which will be available on the CMS website approximately 2 weeks prior to the meeting at *https://www.cms.gov/Regulations-and-Guidance/Guidance/FACA/AdvisoryPanelonClinicalDiagnosticLaboratoryTests.html.* A preliminary agenda is described in section II. of this notice.

ADDRESSES: The Panel meeting will be held *virtually* and *in-person* at the campus of the Centers for Medicare &

Medicaid Services (CMS), Central Building, 7500 Security Boulevard, Baltimore, Maryland 21244–1850.

FOR FURTHER INFORMATION CONTACT: The CLFS Policy Team via email, *CDLTPanel@cms.hhs.gov*; or Rasheeda Arthur, Ph.D. (410) 786–3434. The CMS Press Office, for press inquiries, (202) 690–6145.

SUPPLEMENTARY INFORMATION:

I. Background

The Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests (CDLTs) (the Panel) is authorized by section 1834A(f)(1) of the Social Security Act (the Act) (42 U.S.C. 1395m-1), as established by section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L. 113–93), enacted on April 1, 2014. The Panel is subject to the Federal Advisory Committee Act (FACA), as amended (5 U.S.C. Appendix 2), which sets forth standards for the formation and use of advisory panels.

Section 1834A(f)(1) of the Act directs the Secretary of the Department of Health and Human Services (the Secretary) to consult with an expert outside advisory panel established by the Secretary, composed of an appropriate selection of individuals with expertise in issues related to clinical diagnostic laboratory tests, which may include the development, validation, performance, and application of such tests. Such individuals may include molecular pathologists, researchers, and individuals with expertise in laboratory science or health economics.

The Panel will provide input and recommendations to the Secretary and the Administrator of the Centers for Medicare & Medicaid Services (CMS), on the following:

- The establishment of payment rates under section 1834A of the Act for new clinical diagnostic laboratory tests, including whether to use ''crosswalking'' or ''gapfilling'' processes to determine payment for a specific new test.
- The factors used in determining coverage and payment processes for new clinical diagnostic laboratory tests.
- Other aspects of the payment system under section 1834A of the Act.

A notice announcing the establishment of the Panel and soliciting nominations for members appeared in the October 27, 2014 **Federal Register** (79 FR 63919 through 63920). In the August 7, 2015 **Federal Register** (80 FR 47491), we announced membership appointments to the Panel along with the first public meeting date for the Panel, which was held on August 26, 2015. Subsequent meetings of the Panel and membership appointments were also announced in the **Federal Register**. The Secretary approved rechartering of the Panel on April 24, 2025. The new charter is effective through April 24, 2027 and may be found on the CMS website at *https://www.cms.gov/Regulations-and-Guidance/Guidance/FACA/AdvisoryPanelonClinicalDiagnosticLaboratoryTests.html*. Another notice requesting nominations to the Panel appeared in the September 29, 2017 **Federal Register** (82 FR 45590 through 45592). In that notice, we indicated that nominations would be accepted on a continuous basis. As a result of that notice, the Secretary's designee approved the appointment of the following new Panel members (along with term period):

Gillian Hooker, Ph.D., (October 2024 through October 2027)
Jerry Garner, MBA—HCA, PAHM (October 2024 through October 2027)
Christine Schmotzer, M.D. (May 2025 through May 2028)
Megan Landsverk, Ph.D., New Panel Chair (June 2025 through June 2028)
Alina Bridges, DO (January 2026 through January 2029)

The new Panel member appointments are for 3-year terms.

Other Panel members include:

- Vickie Baselski, Ph.D.
- Pranil Chandra, D.O.
- Chris Chong, MD
- Lennerz Jochen, M.D., Ph.D. M Sc
- Jiang Liuyan, MD
- Marc Rumpler, Ph.D.
- Michele Schoonmaker, Ph.D.
- Heather Shappell, MS, CGC

Unless extended, their terms will expire in August 30, 2027.

II. Agenda

The Agenda for the July 14 and July 15, 2026, hybrid Panel meeting will provide for discussion and comment on the following topics as designated in the Panel's charter:

- Calendar Year (CY) 2027 Clinical Laboratory Fee Schedule (CLFS) new and reconsidered test codes, which will be posted on the CMS website at *https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/Laboratory_Public_Meetings.html*.
- Other CY 2027 CLFS issues designated in the Panel's charter and further described on our Agenda.

A detailed Agenda will be posted approximately 2 weeks before the meeting, on the CMS website at *https://www.cms.gov/medicare/payment/fee-schedules/clinical-laboratory-fee-schedule-clfs/clfs-advisory-panel*. The Panel will make recommendations to the Secretary and the Administrator of CMS regarding crosswalking and gapfilling for new and reconsidered laboratory tests discussed during the CLFS Annual Public Meeting for CY 2027. The Panel will also provide input on other CY 2027 CLFS issues that are designated in the Panel's charter and specified on the meeting agenda.

III. Meeting Participation

This meeting is open to the public. Stand-by speakers may participate in the meeting in-person, via teleconference, and webinar. A stand-by speaker is an individual who will speak on behalf of a company or organization if the Panel has any questions during the meeting about technical information described in the public comments or presentation previously submitted or presented by the organization or company at the recent CLFS Annual Public Meeting for CY 2027 on June 10, 2026. The public may also attend the hybrid meeting in-person or view and/or listen-only to the meeting via teleconference and webinar. Please note that CMS reserves the right to shift the meeting format from hybrid to virtual-only, if for some reason, a hybrid format is not possible. If there is a need to shift to a virtual-only format, we will alert the public as soon as possible and post updated information on the CMS website at *https://www.cms.gov/medicare/payment/fee-schedules/clinical-laboratory-fee-schedule-clfs/clfs-advisory-panel*.

IV. Registration Instructions

Beginning May 1, 2026 and ending May 29, 2026 at 5:00 p.m. E.D.T., registration may be completed by stand-by speakers and in-person attendees. Individuals who intend to view and/or listen to the meeting virtually do not need to register. Stand-by speakers and individuals who intend to attend the meeting at the CMS campus must register online at *https://www.cms.gov/medicare/payment/fee-schedules/clinical-laboratory-fee-schedule-clfs/clfs-advisory-panel*. On this web page, under the heading ''Meeting'' there is a link entitled ''Register for Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests Meeting.'' Click this link and enter the required information. All of the following information must be submitted when registering:

- Name.
- Indicate if individual is registering as a ''Stand-by speaker'' or ''In-Person Attendee.''
- Organization or company name.

• Email addresses that will be used by the speaker to connect to the virtual meeting.

• Indicate if individual is a ''Foreign National'' visitor. Note: An additional review process is required for all foreign national visitors.

• Indicate any new or reconsidered code(s) for which a presentation or comment was submitted, if applicable.

Registration details may not be revised once they are submitted. If registration details require changes, a new registration entry must be submitted by the date specified in the **DATES** section of this notice. Additionally, registration information must reflect individual-level content and not reflect an organization name. Also, we request organizations register all individuals at the same time. That is, one individual may register multiple individuals at the same time. Individuals who are not registered in advance will not be permitted to enter the building (see section VI. of this notice).

After registering, a confirmation email will be sent upon receipt of the registration. The email will provide information to the attendee in preparation for the meeting. Registration is only required for stand-by speakers and members of the public attending the meeting at the CMS campus (address specified in the **ADDRESSES** section of this notice). All registration must be submitted by the deadline specified in the **DATES** section of this notice. Note: No registration is required for participants who plan to view the Panel meeting via webinar or listen via teleconference.

V. Panel Recommendations and Discussions

The Panel's recommendations regarding new and reconsidered test codes for CY 2027 will be posted approximately 2 weeks after the meeting on the CMS website at *https://www.cms.gov/Regulations-and-Guidance/Guidance/FACA/AdvisoryPanelonClinicalDiagnosticLaboratoryTests.html.*

VI. Security, Building, and Parking Guidelines

The hybrid meeting will be held in a Federal government building; therefore, Federal security measures are applicable. In planning your arrival time, we recommend allowing additional time to clear security. We suggest that you arrive at the CMS campus and parking facilities between 9:00 a.m. and 10:00 a.m. E.D.T., so that you will be able to arrive promptly at the meeting by 10:00 a.m. E.D.T. Individuals who are not registered in advance will not be permitted to enter the building and will be unable to attend the meeting. We note that the public may not enter the CMS building earlier than 9:15 a.m. E.D.T. (45 minutes before the convening of the meeting).

Security measures include the following:

• Presentation of government-issued photographic identification to the Federal Protective Service or Guard Service personnel. Persons without proper identification may be denied access to the building.

• Interior and exterior inspection of vehicles (this includes engine and trunk inspection) at the entrance to the grounds. Parking permits and instructions will be issued after the vehicle inspection.

• Passing through a metal detector and inspection of items brought into the building. We note that all items brought to CMS, whether personal or for the purpose of demonstration or to support a demonstration, are subject to inspection. We cannot assume responsibility for coordinating the receipt, transfer, transport, storage, set-up, safety, or timely arrival of any personal belongings or items used for demonstration or to support a demonstration.

VII. Special Accommodations

Individuals attending, viewing, or listening to the meeting who are hearing or visually impaired and have special requirements, or a condition that requires special assistance, must send an email to the resource box (*CDLTPanel@cms.hhs.gov*). The deadline for submitting this request is listed in the **DATES** section of this notice.

VIII. Copies of the Charter

The Secretary's Charter for the Medicare Advisory Panel on CDLTs is available on the CMS website at *http://cms.gov/Regulations-and-Guidance/Guidance/FACA/AdvisoryPanelonClinicalDiagnosticLaboratoryTests.html* or you may obtain a copy of the charter by submitting a request to the contact listed in the **FOR FURTHER INFORMATION CONTACT** section of this notice.

IX. Collection of Information Requirements

This document does not impose information collection requirements, that is, reporting, recordkeeping or third-party disclosure requirements. Consequently, there is no need for review by the Office of Management and Budget under the authority of the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 *et seq.).*

The Administrator of the Centers for Medicare & Medicaid Services (CMS), Mehmet Oz having reviewed and approved this document, authorizes Vanessa Garcia, who is the Federal Register Liaison, to electronically sign this document for purposes of publication in the **Federal Register**.

Vanessa Garcia,

Federal Register Liaison, Centers for Medicare & Medicaid Services.

[FR Doc. 2026–08512 Filed 4–30–26; 8:45 am]

BILLING CODE 4120–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

[CMS–1863–N]

Medicare Program; Meeting Announcement for the Public and the Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests—September 2026

AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.

ACTION: Notice.

SUMMARY: This notice announces meeting dates for a Clinical Laboratory Fee Schedule (CLFS) public meeting that includes the Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests (the Panel) on Tuesday, September 15, 2026 and Wednesday, September 16, 2026. The purpose of the Panel is to advise the Secretary of the Department of Health and Human Services and the Administrator of the Centers for Medicare & Medicaid Services on issues related to clinical diagnostic laboratory tests (CDLTs). During the meeting, the public will have an opportunity to present recommendations (including data on which recommendations are based) on the appropriate basis for establishing payment amounts for CDLTs (crosswalking or gapfilling) for which CMS received no applicable information during the data reporting period from May 1, 2026 through July 31, 2026 to calculate Medicare payment rates. After the public provides this input, the Panel will provide its recommendations to the Secretary and the Administrator on payment recommendations for these CDLTs.

DATE:

Meeting Date: Tuesday, September 15, 2026 and Wednesday, September 16, 2026, from 10:00 a.m. to 4:00 p.m. Eastern Daylight Time (E.D.T.).